Table 1.
Application | Incidence | Daily Oral Dose [mg] | Organ | Methadone [µM] | Patient Number | Ref. |
---|---|---|---|---|---|---|
anti-glioma therapy | methadone maintenance | 30 | blood | 0.59–0.67 | 1 | [19] |
drug substitution | methadone maintenance | 83.3 * | blood | 1.5 * 2 # | 104 | [46] |
drug abuse | methadone-associated death | Blood | 2.6 * 14.5 # | 17 | [38] | |
brain | 12.0 *,$ | 17 | ||||
drug substitution/drug abuse | methadone-associated death | 20–80 | Blood | 1.6 ** 10.6 # | 15 | [37] |
brain | 2.2 **,$ 8.6 #,$ | 15 | ||||
CSF | 0.7 ** 2.8 # | 8 | ||||
drug substitution/drug abuse | § methadone-associated death | blood | 2.6 * (2.3 **) 8.5 # | 52 | [47] | |
drug substitution/drug abuse | § methadone-associated death | blood | 1.3 * (2.3 **) 9.7 # | 11 | [48] |
$ roughly estimated from ng/g data under the assumption of equal distribution between all intracellular and extracellular compartments; * mean; ** median; # highest value; § not in combination with other drugs; CSF: cerebrospinal fluid.